



# InPOG Newsletter



Jan-Apr 2018, Vol 4, Issue 1

## InPOG Executive

Sripad Banavali (Chair)  
Revathy Raj (Co-Chair)  
Ramandeep Arora (Sec)  
Amita Mahajan  
Girish Chinnaswamy  
Nita Radhakrishnan

## Subcommittee Chairs

ALL	Shekhar Krishnan
AML	Smita Kayal
Ch Myelop	Tulika Seth
HL	Amita Mahajan
NHL	Manas Kalra
Histiocytosis	Revathy Raj
CNS	Anirban Das
NBL	Vikramjit Kanwar
Retino	Santosh Honavar
Renal	
Liver	Sandeep Agarwala
PNET	Atul Batra
Osteo	Ashish Gulia
STS	Arpita Bhattacharya
GCT	Venkatraman Radhakrishnan
Rare, epith	Harsha Prasad
HSCT	Satya Yadav
Acc to Care	Shruti Kakkar
Supportive	Maya Prasad
Epidemiology	Hari Sankaran
Late effects	Rachna Seth
Palliative	Gayatri Palat
Can Genetics	Nita Radhakrishnan

Dear Friends,

We are happy to update you on the progress made since the beginning of the year. Our current membership stands at 180 (94 registered, 57 associate and 29 trainee). The trainee membership category is new and is intended to provide fellows in their DM, FNB or IAP Fellowship an opportunity to get exposed to the development of multicentre clinical trials in India. Each of them has been allocated to three to four subcommittees of their interest.

Four InPOG studies have finished recruitment and are now in the process of data collection and/or analysis. Two new studies from neuroblastoma subcommittee have received provisional registration while a study each on CML and Hodgkin disease have completed the registration process and are now fully registered. They should begin recruiting soon. It is noteworthy that InPOG-HL-17-02 is the first multicentre study in India on relapsed cancer in childhood. Four previous studies have been de-registered due to lack of progress. These include InPOG-SUPP-16-01, InPOG-SUPP-16-02, InPOG-SCT-16-01 and InPOG-LIV-16-01. We thank the Principal Investigator's of these studies for their efforts and recognize that despite best efforts and intentions, sometimes planned studies fail to get off the ground.

We are looking for new Chair for the Wilms Subcommittee and would welcome anyone interested to contact us. There has also been a change in our email address. **Please note: The new email address for all future InPOG communication is [inpogexec@gmail.com](mailto:inpogexec@gmail.com).**

The Mid-Term PHO IAP CME is in Bhubhaneshwar on the 30<sup>th</sup> of June and 1<sup>st</sup> of July. A great academic program is under development and the organizers have also provided time for InPOG session from 5 pm on the 30<sup>th</sup> of June. We thank the organizers for this and will send you more details about the InPOG session closer to the date.

## Study Summary Portfolio

Subcommittee	Provisional Registration	Full Registration	Recruitment Ongoing	Recruitment Complete
ALL			InPOG-ALL-15-01	
AML			InPOG-AML-16-01	
Ch Myelop Dis		InPOG-CML-16-01		
HL		InPOG-HL-17-02		InPOG-HL-15-01
NHL				InPOG-NHL-16-01
Histiocytosis			InPOG-HIST-17-01	
CNS				
Neuroblastoma	InPOG-NB-18-01 InPOG-NB-18-02			
Retinoblastoma	InPOG-RB-17-01			
Renal	InPOG-WT-16-01			
Liver				
Osteosarcoma				
PNET			InPOG-PNET-16-01	
Soft Tissue Sarcoma				
Germ Cell Tumours				
Rare, Epithelial	InPOG-RARE-17-02	InPOG-RARE-17-01		
HSCT				
Access to Care	InPOG-ACC-16-02			InPOG-ACC-16-01 InPOG-ACC-16-03
Supportive Care				
Epidemiology	InPOG-EPI-16-01			
Late Effects		InPOG-LE-17-02	InPOG-LE-16-01	
Palliative Care				
Cancer Genetics	InPOG-CANGEN-16-01			

## InPOG Studies - Recruitment Complete

InPOG-HL-15-01

A collaborative study for newly diagnosed childhood Hodgkin's lymphoma patients in India

<b>Principal Investigator</b>	Prof Jagdish Chandra
<b>Registered with InPOG</b>	June 2015
<b>CTRI Registration</b>	CTRI/2016/03/010916
<b>Recruitment commenced</b>	August 2015
<b>Currently patients recruited</b>	409
<b>Target patient recruitment</b>	350 revised to 400
<b>Anticipated duration of recruitment</b>	3 years
<b>Recruitment Closed</b>	February 2018
<b>Centers study open in</b>	27 centres

- All India Institute of Medical Sciences, New Delhi
- All India Institute of Medical Sciences, Patna
- Amrita Institute of Medical Sciences, Kochi
- Asian Institute of Oncology, Mumbai
- Banaras Hindu University, Varanasi
- Cancer Institute, Chennai
- Christian Medical College, Ludhiana
- Deenanath Mangeshkar Hospital, Pune
- Fortis Memorial Research Institute, Gurgaon
- Government Medical College, Jammu
- GVN Cancer Institute, Trichy
- Hematology-Oncology Clinic, Ahmedabad
- Indraprastha Apollo Hospital, New Delhi
- Institute Rotary Cancer Hospital, AIIMS, New Delhi
- JIPMER, Puducherry
- Kalawati Children's Hospital, New Delhi
- King George's medical University, Lucknow
- Mahaveer Cancer Sansthan, Patna
- Max Super Specialty Hospital, Saket, New Delhi
- Mazumdar Shaw Cancer Centre, Bangalore
- Meenakshi Mission Hospital & Research Centre, Madurai
- MNJ Cancer Hospital, Hyderabad
- Rainbow Children's Hospital, Hyderabad
- Rajiv Gandhi Cancer Institute, New Delhi
- Regional Cancer Centre, Thiruvananthipuram
- Saroj Gupta Cancer Centre and research Institute, Kolkata
- Sir Ganga Ram Hospital, New Delhi

### **InPOG NHL-16-01**

#### **A Retrospective Multi-centric Study of Contemporary Epidemiology & Outcome of Childhood B-NHL in India**

<b>Principal Investigator</b>	Dr Amita Trehan
<b>Registered with InPOG</b>	October 2016
<b>CTRI Registration</b>	
<b>Recruitment commenced</b>	Yes
<b>Currently patients recruited</b>	238
<b>Target patient recruitment</b>	300-400
<b>Anticipated duration of recruitment</b>	6 months
<b>Recruitment Closed</b>	April 2018
<b>Centers study open in</b>	10 centres

- All India Institute of Medical Sciences, New Delhi
- Cancer Institute, Chennai
- Indraprastha Apollo Hospital, New Delhi
- Institute Rotary Cancer Hospital, AIIMS, New Delhi - **NEW**
- Max Super Specialty Hospital, Patparganj, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- Post Graduate Institute of Medical Education & Research, Chandigarh
- Rainbow Hospital, Hyderabad
- Rajiv Gandhi Cancer Institute, New Delhi
- Tata Medical Centre, Kolkata

### **InPOG-ACC-16-01**

#### **Multi-site Prospective Study to Determine Household Out-of-Pocket Expenditure Incurred by Families of Children Newly Diagnosed with Cancer in India (HOPE Study)**

<b>Principal Investigator</b>	Dr Ramandeep Singh Arora
<b>Registered with InPOG</b>	August 2016
<b>CTRI Registration</b>	CTRI/2016/11/007492
<b>Recruitment commenced</b>	July 2016
<b>Currently patients recruited</b>	402
<b>Target patient recruitment</b>	380-400
<b>Anticipated duration of recruitment</b>	1 year
<b>Recruitment Closed</b>	November 2017
<b>Centers study open in</b>	15 centres

- All India Institute of Medical Sciences, New Delhi
- Apollo Hospital, Chennai
- Asian Institute of Oncology, Mumbai
- BJ Wadia Hospital, Mumbai
- Cancer Institute, Chennai
- Indraprastha Apollo Hospital, New Delhi
- Institute of Child Health, Chennai
- Institute Rotary Cancer Hospital, AIIMS, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- Safdarjung Hospital, New Delhi
- Saroj Gupta Cancer Centre and research Institute, Kolkata
- SION Hospital, Mumbai
- Sri Ramachandra Medical Centre, Chennai
- Tata Medical Centre, Kolkata
- Tata Memorial Hospital, Mumbai

### **InPOG-ACC-16-03**

#### **Exploring Barriers and Enablers to Accessing Care for Childhood Cancers in India: A Multi-centre Qualitative Study**

<b>Principal Investigator</b>	Dr Ramandeep Singh Arora
<b>Registered with InPOG</b>	May 2017
<b>CTRI Registration</b>	No
<b>Recruitment commenced</b>	November 2017
<b>Currently patients recruited</b>	34 patients + 27 healthcare providers
<b>Target patient recruitment</b>	30-40 patients + 15-20 healthcare providers
<b>Anticipated duration of recruitment</b>	3 months
<b>Recruitment Closed</b>	January 2018
<b>Centers study open in</b>	7 centres

- All India Institute of Medical Sciences, New Delhi
- Indo-American Cancer Institute, Hyderabad
- Indraprastha Apollo Hospital, New Delhi
- Institute Rotary Cancer Hospital, AIIMS, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- MNJ Cancer Hospital, Hyderabad
- Rainbow Hospital, Hyderabad

## InPOG Studies - Recruitment Ongoing

### InPOG-ALL-15-01

**An Indian Childhood Collaborative Leukemia Group multicentre national standardization study for newly diagnosed acute lymphoblastic leukemia**

<b>Principal Investigator</b>	Prof Vaskar Saha
<b>Registered with InPOG</b>	July 2015
<b>CTRI Registration</b>	CTRI/2015/12/006434
<b>Recruitment commenced</b>	Oct 2016
<b>Currently patients recruited</b>	299
<b>Target patient recruitment</b>	2240
<b>Centers study open in</b>	5 centres

- All India Institute of Medical Sciences, New Delhi
- Cancer Institute, Chennai
- PGIMER, Chandigarh
- Tata Medical Centre, Kolkata
- Tata Medical Centre, Mumbai – **NEW**

### InPOG-AML-16-01

**Randomized Phase III Study Comparing DA (3+7) Versus ADE as Induction Chemotherapy in children with Acute Myeloid Leukemia**

<b>Principal Investigator</b>	Dr Venkatraman Radhakrishnan
<b>Registered with InPOG</b>	April 2016
<b>CTRI Registration</b>	CTRI/2014/11/005202
<b>Recruitment commenced</b>	July 2014
<b>Currently patients recruited</b>	85
<b>Target patient recruitment</b>	700
<b>Anticipated duration of recruitment</b>	5 years
<b>Centers study open in</b>	4 centres

- Cancer Institute, Chennai
- Institute Rotary Cancer Hospital, AIIMS, New Delhi
- JIPMER, Puducherry
- MNJ Cancer Hospital, Hyderabad

## InPOG-LE-16-01

### The Indian Childhood Cancer Survivorship Study (C2S study): After treatment completion registry of childhood cancers – Phase 1

<b>Principal Investigator</b>	Dr Rachna Seth
<b>Registered with InPOG</b>	May 2016
<b>CTRI Registration</b>	
<b>Recruitment commenced</b>	June 2016
<b>Currently patients recruited</b>	639
<b>Target patient recruitment</b>	At least 500 (desirable 1000)
<b>Anticipated duration of recruitment</b>	5 years
<b>Centers study open in</b>	12 centres

- All India Institute of Medical Sciences, New Delhi
- Banaras Hindu University, Varanasi – **NEW**
- Cancer Institute, Chennai
- Indraprastha Apollo Hospital, New Delhi
- Kalawati Children's Hospital, New Delhi
- King George's medical University, Lucknow
- Max Super Specialty Hospital, Patparganj, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- Rajiv Gandhi Cancer Institute, New Delhi
- Regional Cancer Centre, Thiruvananthipuram
- SION Hospital, Mumbai
- Tata Medical Centre, Kolkata

## InPOG-PNET-16-01

### Evaluation of clinicopathological characteristics, prognostic factors and treatment outcomes in patients with PNET of Kidney: An InPOG study

<b>Principal Investigator</b>	Dr Bivas Biswas
<b>Registered with InPOG</b>	June 2016
<b>CTRI Registration</b>	
<b>Recruitment commenced</b>	Yes
<b>Currently patients recruited</b>	30
<b>Target patient recruitment</b>	At least 50
<b>Anticipated duration of recruitment</b>	6 months
<b>Centers study open in</b>	2 centres

- Institute Rotary Cancer Hospital, AIIMS, New Delhi
- Tata Medical Centre, Kolkata

## InPOG-HIST-17-01

### Indian Hemophagocytic Lymphohistiocytosis Registry (I-HLH): Establishment of a nationwide prospective web-based registry for patients diagnosed with HLH

<b>Principal Investigator</b>	Dr Mukesh Desai
<b>Registered with InPOG</b>	July 2017
<b>CTRI Registration</b>	Ongoing
<b>Recruitment commenced</b>	Yes
<b>Currently patients recruited</b>	3
<b>Target patient recruitment</b>	300
<b>Anticipated duration of recruitment</b>	5 years
<b>Centers study open in</b>	8 centres

- BJ Wadia Hospital, Mumbai – **NEW**
- Indira Gandhi Institute of Child Health, Bangalore – **NEW**
- Kanchi Kamakoti Childs Trust Hospital, Chennai
- Max Smart Super Specialty Hospital, Saket, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- Max Super Specialty Hospital, Patparganj, New Delhi
- National Institute of Immunohaematology, Mumbai – **NEW**



## **InPOG Studies Granted Full Registration**

### **InPOG-RARE-17-01**

#### **Clinical Course, Pathological Spectrum and Outcomes in Paediatric Rare Tumours in India: A Multicentric Observational Study**

<b>Principal Investigator</b>	Dr Maya Prasad
<b>Registered with InPOG</b>	July 2017
<b>CTRI Registration</b>	
<b>Recruitment commenced</b>	No
<b>Currently patients recruited</b>	NA
<b>Target patient recruitment</b>	250
<b>Anticipated duration of recruitment</b>	1 year
<b>Centers study open in</b>	NA

### **InPOG-LE-17-02**

#### **Cross-Sectional Study of Late Effects in Long term Survivors of Childhood Hodgkin Lymphoma**

<b>Principal Investigator</b>	Dr Maya Prasad
<b>Registered with InPOG</b>	Nov 2017
<b>CTRI Registration</b>	
<b>Recruitment commenced</b>	No
<b>Currently patients recruited</b>	NA
<b>Target patient recruitment</b>	300
<b>Anticipated duration of recruitment</b>	1 year
<b>Centers study open in</b>	NA

**InPOG-CML-16-01 – NEW**

**Study of treatment and outcome of chronic myeloid leukemia in children and adolescents in India.**

<b>Principal Investigator</b>	Dr Deepak Bansal
<b>Registered with InPOG</b>	Feb 2018
<b>CTRI Registration</b>	
<b>Recruitment commenced</b>	No
<b>Currently patients recruited</b>	NA
<b>Target patient recruitment</b>	150
<b>Anticipated duration of recruitment</b>	Not specified
<b>Centers study open in</b>	NA

**InPOG-HL-17-02 – NEW**

**Prospective Collaborative Study for Relapsed/Refractory Hodgkin Lymphoma**

<b>Principal Investigator</b>	Dr Amita Mahajan
<b>Registered with InPOG</b>	May 2018
<b>CTRI Registration</b>	
<b>Recruitment commenced</b>	No
<b>Currently patients recruited</b>	NA
<b>Target patient recruitment</b>	100
<b>Anticipated duration of recruitment</b>	3 years
<b>Centers study open in</b>	NA

## **InPOG Studies Granted Provisional Registration**

1. **InPOG-EPI-16-01 (P)**. Association of gender and childhood cancer registration in India. **PI: Hari Sankaran**
2. **InPOG-WT-16-01 (P)**. Indigenously developed Wilms Tumor Protocol. **PI: Sameer Bakhshi**
3. **InPOG-CANGEN-16-01 (P)**. Evaluation of underlying genetic predisposition for acute myeloid leukemia in children and young adults. **PI: IC Verma**
4. **InPOG-ACC-16-02 (P)**. ACCESSing Childhood Cancer Care in India. **PI: Ramandeep Arora**
5. **InPOG-RARE-17-02 (P)** A Multicenter, prospective, pilot study on use of platinum-based chemotherapy for pediatric nasopharyngeal carcinoma and exploration of the role of peripheral (whole) blood Epstein-Barr virus (EBV)-DNA PCR in predicting outcome and detecting relapse. **PI: Anirban Das**
6. **InPOG-RB-17-01 (P)** A Prospective Collaborative Study for Newly Diagnosed patients with Retinoblastoma. **PI: Santosh Honavar**
7. **InPOG-NB-18-01 (P)** India Neuroblastoma Registration and Biology Study. **PI: Vikramjit Kanwar - NEW**
8. **InPOG-NB-18-02 (P)** Indian Non-high risk Neuroblastoma Study. **PI: Vikramjit Kanwar - NEW**